** Drugmaker Regeneron Pharmaceuticals' REGN.O shares fall 7% to $568 premarket
** Co posts Q1 adj. profit of $8.22/shr, missing analysts' estimates of $8.82, according to data compiled by LSEG
** Reports Q1 revenues of $3.03 billion vs estimates of $3.27 billion
** Says global sales for its blockbuster lung disease drug, Dupixent, rose 19% in Q1 to $3.67 billion
** However, U.S. sales of dry eye disease drugs Eylea and Eylea HD fell 26% to $1.4 billion
** "While we anticipated this may be a more messy quarter for Eylea due to ongoing funding concerns for patient assistance charities, other factors further exacerbated this dynamic" - Brokerage BMO Capital Markets
** As of last close, REGN has fallen 14.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.